Therapeutic drug monitoring to adjust dosing in morbid obesity - a new use for an old methodology

British Journal of Clinical Pharmacology

Volumn 73, Issue 5, 2012, Pages 685-690

  Martin, Jennifer H ^a,b   Saleem, Mohamed ^a,c   Looke, David ^a,b  

^a UNIVERSITY OF QUEENSLAND   (Australia)

^b PRINCESS ALEXANDRA HOSPITAL   (Australia)

^c INSTITUTE OF MEDICAL AND VETERINARY SCIENCE   (Australia)

Author keywords

Antimicrobials; Obesity; Therapeutic drug monitoring

Indexed keywords

AMINOGLYCOSIDE ANTIBIOTIC AGENT; BETA LACTAM; CARBOPLATIN; CISPLATIN; CYTOCHROME P450 1A2; CYTOCHROME P450 2D6; CYTOCHROME P450 3A; DAPTOMYCIN; ERTAPENEM; ESTROGEN RECEPTOR; ETOPOSIDE; QUINOLINE DERIVED ANTIINFECTIVE AGENT; TOPOTECAN; VANCOMYCIN;

ADIPOSE TISSUE; ARTICLE; BLOOD FLOW; BODY SIZE; CAUSE OF DEATH; CHEMOTHERAPY; CLINICAL PRACTICE; COST EFFECTIVENESS ANALYSIS; CRITICAL ILLNESS; DRUG MONITORING; ECONOMIC ASPECT; HEART OUTPUT; HUMAN; INCIDENCE; INSULIN RESISTANCE; KIDNEY FUNCTION; LEG EDEMA; LIVER FUNCTION; MINIMUM INHIBITORY CONCENTRATION; MORBID OBESITY; MORBIDITY; MORTALITY; PHARMACOGENETICS; PLASMA CONCENTRATION-TIME CURVE; PRACTICE GUIDELINE; PREVALENCE; PRIORITY JOURNAL; PROTEIN BINDING; PUBLIC HEALTH PROBLEM; SOCIAL JUSTICE; SOCIOECONOMICS; VASCULAR RESISTANCE;

ANTI-INFECTIVE AGENTS; BODY MASS INDEX; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG DOSAGE CALCULATIONS; DRUG MONITORING; HUMANS; METABOLIC CLEARANCE RATE; OBESITY, MORBID; PREVALENCE;

EID: 84859408321     PISSN: 03065251     EISSN: 13652125     Source Type: Journal    
DOI: 10.1111/j.1365-2125.2011.04159.x     Document Type: Article

References (51)

1. Li Z, Bowerman S, Heber D. Health ramifications of the obesity epidemic. Surg Clin North Am 2005; 85: 681-701.
2. Martin JH, Fay MF, Udy A, Roberts J, Kirkpatrick C, Ungerer J, Lipman J. Pitfalls of using estimations of glomerular filtration rate in an intensive care population. Internal Med J 2011; 41: 537-543.
3. Pai MP, Paloucek FP. The origin of the 'ideal' body weight equations. Ann Pharmacother 2000; 34: 1066-9.
4. Blouin RA, Warren GW. Pharmacokinetic considerations in obesity. J Pharm Sci 1999; 88: 1-7.
5. Janmahasatian S, Duffull S, Ash S, Ward L, Byrne N, Green B. Quantification of lean bodyweight. Clin Pharmacokinet 2005; 44: 1051-65.
6. Erstad BL. Which weight for weight-based dosage regimens in obese patients? Am J Health Syst Pharm 2002; 59: 2105-10.
7. Janmahasatian S, Duffull SB, Ash S, Ward LC, Byrne NM, Green B. Quantification of lean bodyweight. Clin Pharmacokinet 2005; 44: 1051-65.
8. Pearson TC, Guthrie DL, Simpson J, Chinn S, Barosi G, Ferrant A, Lewis SM, Najean Y. Interpretation of measured red cell mass and plasma volume in adults: expert pane on radionuclides of the International Council for Standardization in Haematology. Br J Haematol 1995; 89: 748-56.
9. Nawaratne S, Brien JE, Seeman E, Fabiny R, Zalcberg J, Cosolo W, Angus P, Morgan DJ. Relationships among liver and kidney volumes, lean body mass and drug clearance. Br J Clin Pharmacol 1998; 46: 447-52.
10. Kotlyar M, Carson SW. Effects of obesity on the cytochrome P450 enzyme system. Int J Clin Pharmacol Ther 1999; 37: 8-19. Int J Clin Pharmacol Ther. 1999;37:819.
11. Angiolillo DJ, Fernandez-Ortiz A, Bernardo E, Barrera Ramirez C, Sabate M, Fernandez C, Hernandez-Antolin R, Escaned J, Alfonso F, Macaya C. Platelet aggregation according to body mass index in patients undergoing coronary stenting: should clopidogrel loading-dose be weight adjusted. J Invasive Cardiol 2004; 16: 169-174.
12. Launay-Vacher V, Rey J-B, Isnard-Bagnis C, Deray G, Daouphars M. Prevention of cisplatin nephrotoxicity: state of the art and recommendations from the European Society of Clinical Pharmacy Special Interest Group on Cancer Care. Cancer Chemother Pharmacol 2008; 61: 903-9.
13. Demirovic J, Pai A, Pai M. Estimation of creatinine clearance in morbidly obese patients. Am J Health Syst Pharm 2009; 66: 642-8.
14. Cheymol G. Effects of obesity on pharmacokinetic implications for drug therapy. Clin Pharmacokinet 2000; 39: 215-31.
15. Abernethy D, Greenblatt DJ. Phenytoin disposition in obesity: determination of loading dose. Arch Neurol 1985; 42: 468-71.
16. Derry CL, Kroboth PD, Pittenger AL, Kroboth FJ, Corey SE, Smith RB. Pharmacokinetics and pharmacodynamics of triazolam after two intermittent doses in obese and normal-weight men. J Clin Psychopharmacol 1995; 15: 197-205.
17. Shum L, Jusko W. Effects of obesity and ancillary variables (dialysis time, drug, albumin, and fatty acid concentrations) on theophylline serum protein binding. Biopharm Drug Dispos 1989; 10: 549-62.
18. Hanley MJ, Abernethy DR, Greenblatt DJ. Effect of obesity on the pharmacokinetics of drugs in humans. Clin Pharmacokinet 2010; 49: 71-87.
19. Erstad BL. Dosing of medications in morbidly obese patients in the intensive care unit setting. Intensive Care Med 2004; 30: 18-32.
20. Goossens GH, Karpe F. Human adipose tissue blood flow and micromanipulation of human subcutaneous blood flow, chapter 7. Methods Mol Biol 2008; 456: 97-107. DOI: 10.1007/978-1-59745-245-8_7.
21. Martin J, Krum H. The heart failure journal club: a review of publications on heart failure in American Heart Journal. Eur J Heart Fail 2001; 3: 125-37.
22. Anderson B, Woollard G, Holford N. A model for size and age changes in the pharmacokinetics of paracetamol in neonates, infants and children. Br J Clin Pharmacol 2000; 50: 125-34.
23. Hilmer SN, Tran K, Rubie P, Wright J, Gnjidic D, Mitchell SJ, Matthews S, Carroll PR. Gentamicin pharmacokinetics in old age and frailty. Br J Clin Pharmacol 2011; 71: 224-31.
24. Parkinson A, Mudra D, Johnson C, Dwyer A, Carroll K. The effects of gender, age, ethnicity, and liver cirrhosis on cytochrome P450 enzyme activity in human liver microsomes and inducibility in cultured human hepatocytes. Toxicol Appl Pharmacol 2004; 199: 193-209.
25. Roberts JA, Roberts MS, Semark A, Udy AA, Kirkpatrick CMJ, Paterson DL, Roberts MJ, Kruger P, Lipman J. Antibiotic dosing in the 'at risk' critically ill patient: linking pathophysiology with pharmacokinetics/pharmacodynamics in sepsis and trauma patients. BMC Anesthesiol 2011; 11: 3.
26. Barras M, Kirkpatrick C, Green B. Current dosing of low-molecular-weight heparins does not reflect licensed product labels: an international survey. Br J Clin Pharmacol 2011; 69: 520-8.
27. Field KM, Kosmider S, Jefford M, Michael M, Jennens R, Green M, Gibbs P. Chemotherapy dosing strategies in the obese, elderly, and thin patient: results of a nationwide survey. J Oncol Pract 2008; 4: 108-13.
28. Colleoni M, Li S, Gelber RD, Price KN, Coates AS, Castiglione-Gertsch M, Goldhirsch A. Relation between chemotherapy dose, oestrogen receptor expression, and body-mass index. Lancet 2005; 366: 1108-10.
29. Griggs JJ, Sorbero ME, Lyman GH. Undertreatment of obese women receiving breast cancer chemotherapy. Arch Intern Med 2005; 165: 1267-73.
30. Lyman GH, Dale DC, Crawford J. Incidence and predictors of low dose-intensity in adjuvant breast cancer chemotherapy: a nationwide study of community practices. J Clin Oncol 2003; 21: 4524-31.
31. Madarnas Y, Sawka CA, Franssen E, Bjarnason GA. Are medical oncologists biased in their treatment of the large woman with breast cancer? Breast Cancer Res Treat 2001; 66: 123-33.
32. Shayne M, Crawford J, Dale DC, Culakova E, Lyman GH. Predictors of reduced dose intensity in patients with early-stage breast cancer receiving adjuvant chemotherapy. Breast Cancer Res Treat 2006; 100: 255-62.
33. Shayne M, Culakova E, Poniewierski MS, Wolff D, Dale DC, Crawford J, Lyman GH. Dose intensity and hematologic toxicity in older cancer patients receiving systemic chemotherapy. Cancer 2007; 110: 1611-20.
34. Slaviero KA, Clarke SJ, McLachlan AJ, Blair EYL, Rivory LP. Population pharmacokinetics of weekly docetaxel in patients with advanced cancer. Br J Clin Pharmacol 2004; 57: 44-53.
35. Behan JW, Avramis VI, Yun JP, Louie SG, Mittelman SD. Diet-induced obesity alters vincristine pharmacokinetics in blood and tissues of mice. Pharmacol Res 2010; 61: 385-90.
36. Sørensen BT, Strömgren A, Jakobsen P, Jakobsen A. A limited sampling method for estimation of the carboplatin area under the curve. Cancer Chemother Pharmacol 1993; 31: 324-7.
37. Ghazal-Aswad S, Calvert AH, Newell DR. A single-sample assay for the estimation of the area under the free carboplatin plasma concentration versus time curve. Cancer Chemother Pharmacol 1996; 37: 429-34.
38. Asai G, Ando Y, Saka H, Ando M, Suguira S, Sakai S, Hasegawa Y, Shimokata K. Estimation of the area under the concentration-versus-time curve of carboplatin following irinotecan using a limited sampling model. Eur J Clin Pharmacol 1998; 54: 725-7.
39. Nannan Panday VR, van Warmerdam LJC, Huizing MT, Ten Bokkel Huinink WW, Schellens JHM, Beijnen JH. A limited sampling model for the pharmacokinetics of carboplatin administered in combination with paclitaxel. J Cancer Res Clin Oncol 1999; 125: 615-20.
40. Touw DJ, Neef C, Thomson AH, Vinks AA. Cost-effectiveness of therapeutic drug monitoring: a systematic review. Ther Drug Monit 2005; 27: 10-7.
41. Falagas ME, Athanasoulia AP, Peppas G, Karageorgopoulos DE. Effect of body mass index on the outcome of infections: a systematic review. Obes Rev 2009; 10: 280-9.
42. Pai MP, Bearden DT. Antimicrobial dosing considerations in obese adult patients. Pharmacotherapy 2007; 27: 1081-91.
43. Healy D, Polk R, Garson M, Rock D, Comstcok T. Comparison of steady-state pharmacokinetics of two dosage regimens of vancomycin in normal volunteers. Antimicrob Agents Chemother 1987; 31: 393-7.
44. Vance-Bryan K, Guay DR, Gilliland SS, Rodvold KA, Rotschafer JC. Effect of obesity on vancomycin pharmacokinetic parameters as determined by using a Bayesian forecasting technique. Antimicrob Agents Chemother 1993; 37: 436-40.
45. Blouin R, Bauer LA, Miller DD, Record KE, Griffen WO. Vancomycin pharmacokinetics in normal and morbidly obese subjects. Antimicrob Agents Chemother 1982; 21: 575-80.
46. Bauer LA, Black DJ, Lill JS. Vancomycin dosing in morbidly obese patients. Eur J Clin Pharmacol 1998; 54: 621-5.
47. Traynor AM, Nafziger AN, Bertino JS. Aminoglycoside dosing weight correction factors for patients of various body sizes. Antimicrob Agents Chemother 1995; 39: 545-8.
48. Therapeutic Guidelines. Antibiotic edition 14. 2010. Melbourne Australia.
49. Allard S, Kinzig M, Boivin G, Sörgel F, LeBel M. Intravenous ciprofloxacin disposition in obesity. Clin Pharmacol Ther 1993; 54: 368-73.
50. Pai MP, Norenberg JP, Anderson T, Goade DW, Rodvold KA, Telepak RA, Mercier RC. Influence of morbid obesity on the single-dose pharmacokinetics of daptomycin. Antimicrob Agents Chemother 2007; 51: 2741-7.
51. Dvorchik BH, Damphousse D. The pharmacokinetics of daptomycin in moderately obese, morbidly obese, and matched nonobese subjects. J Clin Pharmacol 2005; 45: 48-56.